ClinicalTrials.gg
CompletedNCT03237845Updated Feb 16, 2023Results posted

Safety and Efficacy in Adult Subjects With Acute Migraines

A Phase 3 interventional study of Rimegepant and Placebo in Migraine, With or Without Aura, sponsored by Pfizer. Completed at 50 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-16.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,499
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.

Enrollment
6th of 32
1,499 · median 618
Started
2017
with 2 others
Phase 3
14 of 32
5 open now
Registered
4th of 32
by date
Lead sponsor
24 of 32
Pfizer

Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 6th largest by enrollment, is one of 3 that started in 2017, is one of 14 in phase 3, and was the 4th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About rimegepant

rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing rimegepant in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines

03

Conditions studied

  • Migraine, With or Without Aura

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Patient has at least 1 year history of migraines (with or without aura), consistent with a diagnosis according to the International Classification of Headache Disorder, 3rd Edition, Beta version[1] including the following:

    • Not more than 8 attacks of moderate or severe intensity per month within last 3 months
    • Consistent migraine headaches of at least 2 migraine headache attacks of moderate or severe intensity in each of the 3 months prior to the Screening Visit and maintains this requirement during the Screening Period
  2. Less than 15 days with headache (migraine or non-migraine) per month in each of the 3 months prior to the Screening Visit and maintains this requirement during the Screening Period
  3. Patients on prophylactic migraine medication are permitted to remain on therapy provided they have been on a stable dose for at least 3 months prior to study entry.
  4. Patients with for use of triptans may be included provided they meet all other study entry criteria.

Key Exclusion Criteria:

  1. Patient history of disease
  2. Patient history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Patients with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS),Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or (TIA) during the 6 months prior to screening.
  3. Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however patients can be included who have stable hypertension and/or diabetes for 3 months prior to being enrolled)
  4. Patient has a current diagnosis of major depression, other pain syndromes, psychiatric conditions (eg, schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, might interfere with study assessments
  5. Patient has a history of gastric, or small intestinal surgery, or has a disease that causes malabsorption.
  6. The patient has a history or current evidence of any significant and/or unstable medical conditions (eg, history of congenital heart disease or arrhythmia, known suspected infection, hepatitisB or C, or cancer) that, in the investigator's opinion, would expose them to undue risk of a significant adverse event (AE) or interfere with assessments of safety or efficacy during the course ofthe trial
  7. History of, treatment for, or evidence of, alcohol or drug abuse within the past 12 months or patients who have met criteria for any significant substance use disorder within thepast 12 months from the date of the screening visit.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,499 participants (actual)

Study arms

  • Experimental
    Rimegepant 75 mg

    Participants were administered a single oral dose of 75 mg of rimegepant tablet on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.

    Drug: Rimegepant

  • Placebo comparator
    Placebo

    Participants were administered a single oral dose of matching placebo tablet for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.

    Drug: Placebo

Interventions

  • 75 mg tablet QD

    Also known as: BHV-3000

  • DrugPlacebo

    Placebo tablet to match rimegepant dose QD

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Freedom From Pain at 2 Hours Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the electronic diary (eDiary). Pain freedom was defined as pain level of none.

    Time frame: 2 Hours post-dose

  2. Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose

    MBS was reported as nausea, photophobia, or phonophobia at migraine onset using the eDiary. Symptom status (absent, present) was assessed post-dose using the eDiary separately for nausea, photophobia, and phonophobia. Freedom from MBS was defined as MBS reported at onset that was absent post-dose.

    Time frame: 2 Hours

Secondary outcomes

  1. Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose

    Photophobia (sensitivity to light) status was measured as absent or present in the eDiary. Freedom from photophobia was defined as photophobia absent.

    Time frame: 2 hours post-dose

  2. Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose

    Phonophobia (sensitivity to sound) status was measured as absent or present in the eDiary. Freedom from phonophobia was defined as phonophobia absent.

    Time frame: 2 hours post-dose

  3. Percentage of Participants With Pain Relief at 2 Hours Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Pain relief was defined as pain level of none or mild.

    Time frame: 2 hours post-dose

  4. Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose

    Nausea status was measured as absent or present in the eDiary. Freedom from nausea was defined as nausea absent.

    Time frame: 2 hours post-dose

  5. Percentage of Participants With Rescue Medication Use Within 24 Hours Post-dose

    Participants who did not experience relief of their migraine headache at the end of 2 hours after dosing with study medication (and after the 2-hour assessments had been completed on the eDiary) were permitted to use the following rescue medications: aspirin, ibuprofen, acetaminophen up to 1000 mg/day (this includes Excedrin Migraine), naproxen (or any other type of nonsteroidal anti-inflammatory drug), antiemetics (e.g., metoclopramide or promethazine), or baclofen. The participant's use of rescue medication was recorded by the participant in a paper diary.

    Time frame: 24 hours post-dose

  6. Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Sustained pain freedom was defined as pain level of none at 2 hours up to 24 hours post-dose with no rescue medication use through 24 hours post-dose.

    Time frame: From 2 hours up to 24 hours post-dose

  7. Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Sustained pain relief was defined as pain level of none or mild at 2 hours up to 24 hours post-dose with no rescue medication use through 24 hours post-dose.

    Time frame: From 2 hours up to 24 hours post-dose

  8. Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Sustained pain freedom was defined as pain level of none at 2 hours up to 48 hours post-dose with no rescue medication use through 48 hours post-dose.

    Time frame: From 2 hours up to 48 hours post-dose

  9. Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Sustained pain relief was defined as pain level of none or mild at 2 hours up to 48 hours post-dose with no rescue medication use through 48 hours post-dose.

    Time frame: From 2 hours up to 48 hours post-dose

  10. Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose

    Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Pain relapse was defined as pain level of mild, moderate, or severe after 2 hours up to 48 hours for the participants who were pain-free at 2 hours post-dose.

    Time frame: From 2 hours up to 48 hours post-dose

  11. Percentage of Participants With Freedom From Functional Disability at 2 Hours Post-dose

    Functional disability level was assessed in the eDiary on a 4-point scale: normal function, mild impairment, severe impairment, required bed rest. Freedom from functional disability was defined as normal function.

    Time frame: 2 hours post-dose

07

Results

Posted Dec 23, 2020

Participant flow

This study was conducted at 50 sites in United States of which 49 sites enrolled at least 1 participant.

Participant flow — Overall Study
MilestoneRimegepant 75 mgPlacebo
Started594592
Treated543543
Completed538542
Not completed5650
Withdrew: Adverse event01
Withdrew: Lost to follow-up1310
Withdrew: Not experienced moderate/severe migraine2631
Withdrew: Non-compliance with study treatment01
Withdrew: Physician decision12
Withdrew: Pregnancy10
Withdrew: Protocol deviation01
Withdrew: Technical problems81
Withdrew: Withdrawal by subject33
Withdrew: Other reasons40

Outcome measures

PrimaryPercentage of Participants With Freedom From Pain at 2 Hours Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the electronic diary (eDiary). Pain freedom was defined as pain level of none.

Time frame:
2 Hours post-dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Freedom From Pain at 2 Hours Post-dose
Percentage of participantsRimegepant 75 mgPlacebo
Percentage of Participants With Freedom From Pain at 2 Hours Post-dose19.6 (16.2 to 22.9)12.0 (9.2 to 14.7)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0006 · Risk difference (rd): 7.6 · 95% CI 3.3 to 11.9
PrimaryPercentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose

MBS was reported as nausea, photophobia, or phonophobia at migraine onset using the eDiary. Symptom status (absent, present) was assessed post-dose using the eDiary separately for nausea, photophobia, and phonophobia. Freedom from MBS was defined as MBS reported at onset that was absent post-dose.

Time frame:
2 Hours
Reported as:
Number · Percentage of Participants
Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose
Percentage of ParticipantsRimegepant 75 mgPlacebo
Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose37.6 (33.5 to 41.7)25.2 (21.6 to 28.9)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = < 0.0001 · Risk difference (rd): 12.4 · 95% CI 6.9 to 17.9
SecondaryPercentage of Participants With Freedom From Photophobia at 2 Hours Post-dose

Photophobia (sensitivity to light) status was measured as absent or present in the eDiary. Freedom from photophobia was defined as photophobia absent.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of Participants
Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose
Percentage of ParticipantsRimegepant 75 mgPlacebo
Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose37.4 (33.1 to 41.7)22.3 (18.6 to 26.0)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = < 0.0001 · Risk difference (rd): 15.1 · 95% CI 9.4 to 20.8
SecondaryPercentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose

Phonophobia (sensitivity to sound) status was measured as absent or present in the eDiary. Freedom from phonophobia was defined as phonophobia absent.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of Participants
Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose
Percentage of ParticipantsRimegepant 75 mgPlacebo
Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose36.7 (31.7 to 41.7)26.8 (22.3 to 31.3)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0039 · Risk difference (rd): 9.9 · 95% CI 3.2 to 16.6
SecondaryPercentage of Participants With Pain Relief at 2 Hours Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Pain relief was defined as pain level of none or mild.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of Participants
Percentage of Participants With Pain Relief at 2 Hours Post-dose
Percentage of ParticipantsRimegepant 75 mgPlacebo
Percentage of Participants With Pain Relief at 2 Hours Post-dose58.1 (53.9 to 62.3)42.8 (38.6 to 47.0)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = < 0.0001 · Risk difference (rd): 15.3 · 95% CI 9.4 to 21.2
SecondaryPercentage of Participants With Freedom From Nausea at 2 Hours Post-dose

Nausea status was measured as absent or present in the eDiary. Freedom from nausea was defined as nausea absent.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of Participants
Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose
Percentage of ParticipantsRimegepant 75 mgPlacebo
Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose48.1 (42.9 to 53.3)43.3 (38.0 to 48.6)
Statistical analysis
  • Rimegepant 75 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.2084 (P-Value ≥ 0.05; therefore, all secondary outcome measures listed after this outcome measure in the hierarchy were not tested.) · Risk difference (rd): 4.8 · 95% CI -2.7 to 12.2
SecondaryPercentage of Participants With Rescue Medication Use Within 24 Hours Post-dose

Participants who did not experience relief of their migraine headache at the end of 2 hours after dosing with study medication (and after the 2-hour assessments had been completed on the eDiary) were permitted to use the following rescue medications: aspirin, ibuprofen, acetaminophen up to 1000 mg/day (this includes Excedrin Migraine), naproxen (or any other type of nonsteroidal anti-inflammatory drug), antiemetics (e.g., metoclopramide or promethazine), or baclofen. The participant's use of rescue medication was recorded by the participant in a paper diary.

Time frame:
24 hours post-dose
Reported as:
Number · Percentage of Participants
Percentage of Participants With Rescue Medication Use Within 24 Hours Post-dose
Percentage of ParticipantsRimegepant 75 mgPlacebo
Percentage of Participants With Rescue Medication Use Within 24 Hours Post-dose21.0 (17.6 to 24.5)37.0 (32.9 to 41.1)
SecondaryPercentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Sustained pain freedom was defined as pain level of none at 2 hours up to 24 hours post-dose with no rescue medication use through 24 hours post-dose.

Time frame:
From 2 hours up to 24 hours post-dose
Reported as:
Number · Percentage of Participants
Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose
Percentage of ParticipantsRimegepant 75 mgPlacebo
Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours Post-dose12.3 (9.5 to 15.1)7.1 (4.9 to 9.3)
SecondaryPercentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Sustained pain relief was defined as pain level of none or mild at 2 hours up to 24 hours post-dose with no rescue medication use through 24 hours post-dose.

Time frame:
From 2 hours up to 24 hours post-dose
Reported as:
Number · Percentage of Participants
Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose
Percentage of ParticipantsRimegepant 75 mgPlacebo
Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-dose42.6 (38.5 to 46.8)26.5 (22.8 to 30.3)
SecondaryPercentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Sustained pain freedom was defined as pain level of none at 2 hours up to 48 hours post-dose with no rescue medication use through 48 hours post-dose.

Time frame:
From 2 hours up to 48 hours post-dose
Reported as:
Number · Percentage of Participants
Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose
Percentage of ParticipantsRimegepant 75 mgPlacebo
Percentage of Participants With Sustained Pain Freedom From 2 to 48 Hours Post-dose9.9 (7.3 to 12.4)6.0 (4.0 to 8.0)
SecondaryPercentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Sustained pain relief was defined as pain level of none or mild at 2 hours up to 48 hours post-dose with no rescue medication use through 48 hours post-dose.

Time frame:
From 2 hours up to 48 hours post-dose
Reported as:
Number · Percentage of Participants
Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose
Percentage of ParticipantsRimegepant 75 mgPlacebo
Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-dose36.3 (32.2 to 40.4)22.6 (19.1 to 26.2)
SecondaryPercentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose

Pain levels were assessed on a 4-point scale (none, mild, moderate, severe) using the eDiary. Pain relapse was defined as pain level of mild, moderate, or severe after 2 hours up to 48 hours for the participants who were pain-free at 2 hours post-dose.

Time frame:
From 2 hours up to 48 hours post-dose
Reported as:
Number · Percentage of Participants
Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose
Percentage of ParticipantsRimegepant 75 mgPlacebo
Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose49.6 (40.1 to 59.1)50.0 (37.8 to 62.1)
SecondaryPercentage of Participants With Freedom From Functional Disability at 2 Hours Post-dose

Functional disability level was assessed in the eDiary on a 4-point scale: normal function, mild impairment, severe impairment, required bed rest. Freedom from functional disability was defined as normal function.

Time frame:
2 hours post-dose
Reported as:
Number · Percentage of Participants
Percentage of Participants With Freedom From Functional Disability at 2 Hours Post-dose
Percentage of ParticipantsRimegepant 75 mgPlacebo
Percentage of Participants With Freedom From Functional Disability at 2 Hours Post-dose32.6 (28.6 to 36.5)23.4 (19.8 to 26.9)

Adverse events

Collected over Serious adverse events (SAEs) were collected from informed consent up to the end of the study, and adverse events (AEs) were collected from randomization up to end of the study (up to 52 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rimegepant 75 mg0/543 (0%)1/543 (0.2%)0/543 (0%)
Placebo0/543 (0%)2/543 (0.4%)0/543 (0%)
Most frequent serious events
Most frequent serious events
EventRimegepant 75 mgPlacebo
Chest PainGeneral disorders0/5431/543
Urinary Tract InfectionInfections and infestations0/5431/543
Back PainMusculoskeletal and connective tissue disorders1/5430/543

Baseline characteristics

The analysis was performed on modified intent to treat (mITT) participants, defined as those who were randomized only once, took study medication, had moderate to severe pain level at migraine onset, and who provided at least 1 post-dose efficacy measurement (i.e., after taking study medication).

Age, Continuous
Age, Continuous(Years)Rimegepant 75 mgPlaceboTotal
Mean40.195 ± 11.869340.910 ± 12.116840.552 ± 11.9932
Sex: Female, Male
Sex: Female, Male(Participants)Rimegepant 75 mgPlaceboTotal
Female479472951
Male5863121
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rimegepant 75 mgPlaceboTotal
Hispanic or Latino7783160
Not Hispanic or Latino460452912
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rimegepant 75 mgPlaceboTotal
American Indian or Alaska Native459
Asian8816
Native Hawaiian or Other Pacific Islander606
Black or African American111118229
White394399793
More than one race14519
Unknown or Not Reported000
Primary Migraine Type
Primary Migraine Type(Participants)Rimegepant 75 mgPlaceboTotal
Migraine without Aura355366721
Migraine with Aura182169351
Randomization Strata, Prophylactic Migraine Medication Use
Randomization Strata, Prophylactic Migraine Medication Use(Participants)Rimegepant 75 mgPlaceboTotal
Yes8989178
No448446894
08

Study locations

50 sites
  • Coastal Clinical Research
    Mobile, Alabama 36608, United States
  • Thunderbird Internal Medicine / Radiant Research, Inc.
    Glendale, Arizona 85306, United States
  • Woodland Research Northwest, LLC
    Rogers, Arkansas 72758, United States
  • eStudySite
    La Mesa, California 91942, United States
  • Collaborative Neuroscience Network, LLC
    Long Beach, California 90806, United States
  • Pharmacology Research Institute
    Los Alamitos, California 90720, United States
  • Pharmacology Research Institute
    Newport Beach, California 92660, United States
  • Pacific Research Partners LLC
    Oakland, California 94607, United States
  • National Research Institute
    Panorama City, California 91402, United States
  • California Neuroscience Research Medical Group, Inc.
    Sherman Oaks, California 91403, United States
  • Clinical Trials of the Rockies
    Denver, Colorado 80209, United States
  • AGA Clinical Trials
    Hialeah, Florida 33012, United States
  • Clinical Neuroscience Solutions
    Jacksonville, Florida 32256, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Meridien Research
    Tampa, Florida 33634, United States
  • Radiant Research, Inc.
    Atlanta, Georgia 30328, United States
  • Savannah Neurology Specialists
    Savannah, Georgia 31406, United States
  • Christie Clinic, LLC
    Champaign, Illinois 61820, United States
  • PMG Research of McFrland Clinic
    Ames, Iowa 50010, United States
  • Heartland Research Associates, LLC
    Augusta, Kansas 67010, United States
  • Heartland Research Associates, LLC
    Newton, Kansas 67114, United States
  • Heartland Research Associates, LLC
    Park City, Kansas 67207, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67205, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • MedPharmics, LLC
    Metairie, Louisiana 70006, United States
  • NECCR Primacare Research, LLC
    Fall River, Massachusetts 02721, United States
  • Albuquerque Neuroscience, Inc.
    Albuquerque, New Mexico 87109, United States
  • Radiant Research, Inc.
    Jamaica, New York 11432, United States
  • PMG Research of Raleigh, Inc.
    Raleigh, North Carolina 27609, United States
  • Wake Research Associates, LLC
    Raleigh, North Carolina 27612, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28401, United States
  • Radiant Research, Inc.
    Cincinnati, Ohio 45236, United States
  • Radiant Research, Inc.
    Columbus, Ohio 43212, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Neurology Diagnostics, Inc.
    Dayton, Ohio 45459, United States
  • Aventiv Research, Inc.
    Dublin, Ohio 43016, United States
  • Summit Research Network (Oregon), Inc.
    Portland, Oregon 97210, United States
  • Oregon Center for Clinical Investigations, Inc
    Salem, Oregon 97301, United States
  • Fieve Clinical Research, Inc.
    Scranton, Pennsylvania 18503, United States
  • Radiant Research, Inc.
    Anderson, South Carolina 85282, United States
  • Clinical Research Associates, Inc.
    Nashville, Tennessee 37203, United States
  • Tekton Research
    Austin, Texas 78745, United States
  • Ventavia Research Group
    Fort Worth, Texas 76104, United States
  • Red Star Research
    Lake Jackson, Texas 77566, United States
  • FMC Science
    Lampasas, Texas 76550, United States
  • PCP for Life
    Magnolia, Texas 77355, United States
  • Research Across America
    Mesquite, Texas 75149, United States
  • Doctors of Internal Medicine, LTD / Radiant Research, Inc.
    Plano, Texas 75093, United States
  • DM Clinical Research
    Tomball, Texas 77373, United States
09

References and documents

Publications

  • Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019 Jul 11;381(2):142-149. doi: 10.1056/NEJMoa1811090. PubMed 31291516 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Jan 2018, 5 months.

Results were first posted in Dec 2020, 2 years 10 months after primary completion. A results delay was requested in Jan 2019.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 5 months is below that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2017
First posted
Aug 3, 2017
StartActual
Jul 27, 2017
Primary completionActual
Jan 25, 2018
CompletionActual
Jan 31, 2018
Results delay requested
Jan 9, 2019
Results first posted
Dec 23, 2020
Last update
Feb 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03237845
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 3, 2017
Start date
Jul 27, 2017
Primary completion
Jan 25, 2018
Completion
Jan 31, 2018
Results posted
Dec 23, 2020
Last update
Feb 16, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimegepant

Start the discussion